Clinical Trial Update: A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update describes ongoing Phase 1/2 studies of Debio 0123 in combination with temozolomide for recurrent/progressive glioblastoma and with te…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Astrocytoma Who
• Glioblastoma Idh-wildtype

Drugs mentioned

• Debio 0123
• Temozolomide (Temozolomide)

Snippet

Sponsor: Debiopharm International SA | Conditions: Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, Astrocytoma, Grade III | Phase 1, Phase 2 | Status: RECRUITING